Akebia Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Akebia Therapeutics

09/05/2024 14:52

* Akebia Therapeutics Inc  AKBA.OQ  reported a quarterly
adjusted
loss of 9 cents​​ per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of -14 cents.  The mean expectation of
three analysts for the quarter was for a loss of 8 cents per
share. Wall Street expected results to range from -11 cents
to -5 cents per share.
    * Revenue fell 18.7% to $32.61 million from a year ago;
analysts
expected $46.09 million. 
    * Akebia Therapeutics Inc's reported EPS for the quarter was
a
loss of 9 cents​.
    * The company reported a quarterly loss of $17.99 million.
    * Akebia Therapeutics Inc shares had fallen by 23.5% this
quarter and gained 12.9% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 14.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Akebia
Therapeutics Inc is $5.00 
This summary was machine generated from LSEG data May 9 at 01:52
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.08          -0.09          Missed
 Dec. 31 2023      -0.04          0.00           Beat
 Sep. 30 2023      -0.08          -0.08          Met
 Jun. 30 2023      -0.02          -0.06          Missed